Topic Archives: Cubist Pharmaceuticals (CBST)

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Elsewhere the sky is the roof of the […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. You can see his biography, previous columns and most recent comments on his Stock Gumshoe page.] “We ran the race,  the race […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]

[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]

Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing […]

Comments

  • Subramania

    Achaogen Appoints Halley Gilbert to Its Board of Directors $AKAO Achaogen, Inc. a clinical-stage biopharmaceutical co...

  • Avatar

    Today I received (yet another) spiel today about how Mark Skousen's oft-touted Elite "SS-4 Income Stream" could make me ...

  • Avatar

    Glenn, I think that the devil (in this case the angels) is/are in the details. The Sec filing regarding the $ZFGN direct...

  • sogiam

    AKAO has a Cubist xSVP on Board- :-) Long. Thanks Dr. KSS! Achaogen Announces Appointment of Greg Stea to Board of ...

  • Avatar

    Like the hire for Trevena (TRVN)with her pain medicine and acute heart failure background with Merck. Trevena Appoint...

  • Avatar

    "One more thing!" -- Colombo I received this over the weekend from S & A Master Series: The four new gram-negat...

  • Avatar

    Following Fierce Biotech article published today rekindles the fire re rumors of CBST as Big Pharma merger/acquisition t...

  • Avatar

    This from CTIX this morning.Exciting times ahead.I think management is executing nicely. Cellceutix Believes Brilacid...

  • Avatar

    AKAO news Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from...

  • Avatar

    Dovetailing into JZ's mantra of buying Big Pharma, Mathew Carr from the Oxford Emerging Trends Trader (a VIP service new...

  • jer_vic

    Oops, didn't dig deep enough. Trius was bought out in Sept. 2013 by Cubist Pharmaceuticals, which is trading ~$76....

  • Avatar

    This from 5/26/11: BOSTON (MarketWatch) -- Shares of Cambridge, Mass.-based Cubist Pharmaceuticals were up 6% in morning...

  • Avatar

    Cubist Pharmaceuticals, the drug is cubicin CBST ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch